Peripheral Artery Disease News and Research

RSS

Peripheral arterial disease (PAD) occurs when leg arteries become narrowed or blocked by plaque. These blockages can result in severe pain for patients, limited physical mobility, and life-threatening non-healing leg ulcers. According to the American Heart Association, this condition affects approximately 8 to 12 million Americans. With only about 25 percent of PAD patients undergoing treatment, it is a disease that is largely under-diagnosed and under-treated. If left untreated, PAD can lead to critical leg ischemia, a condition where not enough blood is being delivered to the leg to keep the tissue alive. Total loss of circulation to the legs and feet can cause gangrene and lead to amputation.

Gut microbiome pattern predicts future heart attack risk in coronary heart disease patients

A specific gut microbiota pattern was found to predict new cardiovascular events in patients with coronary heart disease, based on data from the CORDIOPREV study. Researchers developed a microbiota-based risk score that may improve secondary prevention.

21 Apr 2025

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral semaglutide) significantly reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD).

1 Apr 2025

Study finds high rates of undiagnosed and untreated peripheral artery disease

A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million Americans over the age of 40, is often underdiagnosed and undertreated, with fewer women getting guideline-directed medical therapy than men.

31 Mar 2025

Semaglutide improves maximal walking distance in people with symptomatic PAD and Type 2 diabetes

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and Type 2 diabetes in the first-of-its kind trial to evaluate the use of a GLP-1 agonist to manage PAD.

29 Mar 2025

$Unraveling CD47's role in bone fracture healing$

Unraveling CD47's role in bone fracture healing

Bone fracture healing is a highly coordinated process involving inflammation, fibrovascular formation, and mineralization.

27 Mar 2025

This molecule links your diet to stroke and Alzheimer’s—here’s how to stop it

A new review explores how TMAO, a gut-derived metabolite from red meat and other foods, contributes to heart and brain diseases. It also highlights promising interventions—like plant-based diets, probiotics, and nutraceuticals—to lower TMAO levels and reduce health risks.

26 Mar 2025

Increased mobility linked to lower risk of hospitalization in heart failure patients

Compared with those who spent most of their time in a single room, people with heart failure with preserved ejection fraction (HFpEF) who were able to travel outside of their home without assistance were significantly less likely to be hospitalized or die within a year, according to a study being presented at the American College of Cardiology's Annual Scientific Session (ACC.25).

25 Mar 2025

AI technology in mammograms could predict heart disease in women

Mammograms, with the help of artificial intelligence (AI) models, may reveal much more than cancer, according to a study being presented at the American College of Cardiology's Annual Scientific Session (ACC.25).

20 Mar 2025

People from families with exceptional longevity have lower risk of peripheral artery disease

A new research paper was published in Aging (Aging-US) on February 25, 2025, Volume 17, Issue 2, titled "Epidemiology and genetic determination of measures of peripheral vascular health in the Long Life Family Study."

12 Mar 2025

Limiting TV time may reduce heart disease risk for people with genetic risk for diabetes

Watching no more than one hour of TV a day may lower the risk of heart attack, stroke and other blood vessel diseases among people with varying levels of genetic risk for Type 2 diabetes, including high genetic risk, according to new research published today in the Journal of the American Heart Association, an open access, peer-reviewed journal of the American Heart Association.

12 Mar 2025

Gender gaps in peripheral vascular disease impact diagnosis and treatment

The disparities between men and women in prevalence, risk factors and symptoms of peripheral vascular disease (PVD) have a profound impact on prevention, diagnosis, treatment and outcomes for women, according to a new American Heart Association scientific statement published today in the Association's flagship, peer-reviewed journal Circulation.

11 Mar 2025

Olpasiran significantly lowers "bad cholesterol" linked to cardiovascular risk

The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of cardiovascular events, according to results from an analysis by a Mount Sinai researcher of a phase 2 trial.

13 Feb 2025

Research reveals distinct blood pressure patterns in South Asian and East Asian adults

South Asian and East Asian adults living in the United Kingdom may have distinct trajectories to develop high blood pressure over their life course, according to new research published today in Hypertension, an American Heart Association journal.

12 Feb 2025

Boston Scientific announces agreement to acquire Bolt Medical, Inc.

Boston Scientific Corporation today announced it has entered into a definitive agreement to acquire Bolt Medical, Inc., the developer of an intravascular lithotripsy (IVL) advanced laser-based platform for the treatment of coronary and peripheral artery disease.

From Boston Scientific 13 Jan 2025

Muvalaplin shows promise in lowering Lp(a) levels in clinical trial

A clinical trial testing muvalaplin, a novel oral medication, was able to safely and effectively lower high levels of lipoprotein (a), according to late-breaking science presented today at the American Heart Association's Scientific Sessions 2024.

19 Nov 2024

GLP-1 and SGLT2 inhibitors show promise in preventing recurrent stroke and heart attack

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death in adults who had an initial stroke, according to a preliminary study to be presented at the American Heart Association's Scientific Sessions 2024.

11 Nov 2024

The long-term cardiac impact of COVID-19

Study shows that severe COVID-19 elevates the long-term risk of major adverse cardiac events (MACE), making it comparable to coronary artery disease. It also highlights a genetic interaction with ABO blood type, influencing cardiovascular outcomes.

13 Oct 2024

COVID-19 found to increase heart attack and stroke risks

An analysis of data in the UK Biobank has found that COVID-19 infection may increase the risk of heart attack, stroke and death from any cause for up to three years for people with and without cardiovascular disease, according to new research published today in the American Heart Association's peer-reviewed journal Arteriosclerosis, Thrombosis and Vascular Biology (ATVB).

9 Oct 2024

Study links metal exposure to increased risk of atherosclerosis

Metal exposure from environmental pollution is associated with increased calcium buildup in the coronary arteries at a level comparable to traditional risk factors like smoking and diabetes, according to a study published today in JACC, the flagship journal of the American College of Cardiology.

18 Sep 2024

Research highlights cardiovascular benefits of semaglutide for overweight adults with impaired kidney function

The anti-obesity medication semaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with overweight or obesity who don't have diabetes, whether or not they also have impaired kidney function, according to new research to be presented at this year's Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept).

13 Sep 2024